CDP-choline accumulation in breast and colorectal cancer cells treated with a GSK-3-targeting inhibitor

Abstract

PurposeGlycogen synthase kinase 3 (GSK3) is a key controlling element of many cellular processes including cell-cycle progression and recent studies suggest that GSK3 is a potential anticancer target. Changes in glucose metabolism associated with GSK3 inhibition may impact on lipid synthesis, whilst lipid metabolites can act as molecular response markers.MethodsHere, SKBr3 breast and HCT8 colorectal cancer cells were treated with the GSK3 inhibitor SB216763, and [14C (U)] glucose and [3H] choline incorporation into lipids was determined. Cell extracts from treated cells were subject to 31P NMR spectroscopy.ResultsSB216763 treatment decreased choline incorporation into lipids and caused an accumulation of CDP-choline which was accompanied by decreased conversion of glucose into lipid components.ConclusionSB216763 profoundly inhibits phospholipid synthesis in cancer cells which demonstrate accumulation of CDP-choline detectable by 31P NMR spectroscopy. Metabolic changes in lipid metabolism present potential response markers to drugs targeting GSK3.

Browning of Mammary Fat Suppresses Pubertal Mammary Gland Development of Mice via Elevation of Serum Phosphatidylcholine and Inhibition of PI3K/Akt Pathway

“…In the present study, we found that DOPC inhibited the activation of the PI3K/Akt pathway, while the activator of Akt reversed the inhibitory effects of DOPC on HC11 proliferation. Our results were consistent with the reports that phosphatidylcholine also plays an important role in cell signaling transduction as the phosphatidylcholine transferase could act as a carrier to transport phosphatidylcholine from membrane to membrane [42]. Additionally, increasing the cellular ratio of phosphatidylcholine (20:4-PC) diminished Akt phosphorylation and suppressed cyclin expression [31].…”

UHPLC-HRMS-Based Serum Untargeted Lipidomics: PCs and SMs are the Main disturbed lipid markers to Distinguish Colorectal Advanced Adenoma from Cancer

“…Glycogen synthase kinase 3 (GKS3) has recently been discovered as a possible anticancer target. One research used a GKS3 inhibitor on HCT8 CRC cells and discovered that it caused choline accumulation in the tumor cells (45), which is consistent with prior reports of choline buildup in CRC(46). Therefore, the suppression of GKS3 during CAA carcinogenesis might be another rationale for PC downregulation in CRC.…”